CIM
VERV

CIM Investment Management’s Verve Therapeutics VERV Stock Holding History

CIM Investment Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,378
Closed -$296K – 262
2025
Q2 		$296K Sell
26,378
-461
-2% -$2.63K 0.06% 213
2025
Q1 		$123K Sell
26,839
-669
-2% -$4.48K 0.03% 226
2024
Q4 		$155K Hold
27,508
– – 0.05% 232
2024
Q3 		$133K Hold
27,508
– – 0.04% 242
2024
Q2 		$134K Buy
+27,508
New +$173K 0.04% 237

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CIM Investment Management's VERV Position: Q3 2025 in Review

CIM Investment Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 26,378 shares — an estimated $296K sold.

CIM Investment Management first reported a position in VERV in Q2 2024 and held it in 5 quarters. The position peaked at $296K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • CIM Investment Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CIM Investment Management sold 26,378 Verve Therapeutics shares in Q3 2025, an estimated $296K.
  • CIM Investment Management first reported a position in Verve Therapeutics in Q2 2024 and held it in 5 quarters.
  • CIM Investment Management's Verve Therapeutics position peaked at $296K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on CIM Investment Management's 13F filing for Q3 2025, filed 18 Nov 2025.